New research suggests semaglutide's cardiovascular benefits may occur partly independently of its weight-loss effects. The GLP-1 receptor agonist, known for treating type 2 diabetes and obesity, appears to improve heart health through additional mechanisms. This may broaden its potential use in patients with cardiovascular disease.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.